In HER2-negative breast cancer treatment, more studies on the combination of targeted therapies with other therapies need to be carried out, in order to further study the effectiveness, safety and economics of the combined application of targeted drugs and chemotherapy drugs, so as to maximize the efficacy of targeted breast cancer therapy, which may become a new direction for the treatment of breast cancer patients in the future. The gene discussed is ERBB2; the disease is breast carcinoma.